Benefit from ifosfamide treatment in small-cell lung cancer: A meta‑analysis

Yang,Huizhen; Ma,Yun; Liu,Zhida; Wang,Zheng; Han,Baohui; Ma,Lijun

doi:10.3892/mco.2014.467

Benefit from ifosfamide treatment in small-cell lung cancer: A meta‑analysis

Authors:
- Huizhen Yang
- Yun Ma
- Zhida Liu
- Zheng Wang
- Baohui Han
- Lijun Ma
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China, Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, P.R. China
Published online on: November 25, 2014 https://doi.org/10.3892/mco.2014.467
Pages: 420-424

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was conducted to compare the efficacy and safety of ifosfamide plus etoposide plus platinum (IEP) to that of etoposide plus platinum (EP) in patients with previously untreated small‑cell lung cancer (SCLC). The Cochrane Library, Embase, MEDLINE and Chinese Biomedical Literature databases were searched to identify all randomized controlled trials comparing IEP to EP in patients with histologically proven SCLC. Two investigators independently assessed the quality of the relevant trials and extracted data. We analyzed the data using Review Manager software, version 4.2.8. A total of 4 trials with 447 previously untreated SCLC patients were included in this meta‑analysis. The results of the meta‑analysis indicated that there were no significant differences in the overall response [relative risk (RR) = 1.07, 95% confidence interval (CI): 0.97‑1.19], 1‑year survival rate (RR=1.22, 95% CI: 0.96‑1.55) and 2‑year survival rate (RR=1.52, 95% CI: 0.75‑3.07) between the IEP and EP regimens. However, there were significant differences between the IEP and EP regimens regarding the incidence of grade 3̸4 neutropenia (RR=1.52, 95% CI: 1.07‑2.17) and grade 3̸4 vomiting (RR=1.78, 95% CI: 1.02‑3.11). In conclusion, our results suggested that IEP is not superior to EP regimen for the treatment of previously untreated SCLC, whereas the IEP regimen is associated with more severe hematological and gastrointestinal toxicities compared to EP. Therefore, the use of ifosfamide in multimodality treatment regimens requires further investigation.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	Masters G: The clinical presentation of small cell lung cancerLung Cancer: Principles and Practice. Pass HI, Carbone DP, Johnson DH, Minna JD and Turrisi AT III: 3rd. Lippincott Williams & Wilkins; Philadelphia, PA: pp. 304–314. 2005
3	Jackman DM and Johnson BE: Small-cell lung cancer. Lancet. 366:1385–1396. 2005. View Article : Google Scholar : PubMed/NCBI
4	Turrisi AT III, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 340:265–271. 1999. View Article : Google Scholar : PubMed/NCBI
5	Sorensen M, Pijls-Johannesma M, Felip E, et al: Small-cell-lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21 (Suppl 5):v120–v125. 2010. View Article : Google Scholar : PubMed/NCBI
6	Sambrook RJ and Girling DJ: A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom. Br J Cancer. 84:1447–1452. 2001. View Article : Google Scholar : PubMed/NCBI
7	Jiang L, Yang KH, Guan QL, et al: Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials. Intern Med J. 42:1297–1309. 2012. View Article : Google Scholar : PubMed/NCBI
8	Brade WP, Herdrich K and Varini M: Ifosfamide - pharmacology, safety and therapeutic potential. Cancer Treat Rev. 12:1–47. 1985. View Article : Google Scholar : PubMed/NCBI
9	Havemann K, Wolf M, Drings P, et al: Experience of a German multicenter study group with ifosfamide in small cell lung cancer. Semin Oncol. 16 (Suppl 3):9–18. 1989.PubMed/NCBI
10	Thatcher N, Cerny T, Stout R, et al: Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. Cancer. 60:2382–2387. 1987. View Article : Google Scholar : PubMed/NCBI
11	Wolf M, Havemann K, Holle R, et al: Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. J Clin Oncol. 5:1880–1889. 1987.PubMed/NCBI
12	Evans WK, Stewart DJ, Shepherd FA, et al: VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer. Eur J Cancer. 30A:299–303. 1994. View Article : Google Scholar : PubMed/NCBI
13	Loehrer PJ, Rynard S, Ansari R, et al: Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. Cancer. 69:669–673. 1992. View Article : Google Scholar : PubMed/NCBI
14	Miyamoto H, Nakabayashi T, Isobe H, et al: A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology. 49:431–435. 1992. View Article : Google Scholar : PubMed/NCBI
15	Loehrer PJ Sr, Ansari R, Gonin R, et al: Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol. 13:2594–2599. 1995.PubMed/NCBI
16	Wolff AC, Ettinger DS, Neuberg D, et al: Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol. 13:1615–1622. 1995.PubMed/NCBI
17	Glisson B, Lee JS, Palmer J, et al: Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma. Cancer. 82:301–308. 1998. View Article : Google Scholar : PubMed/NCBI
18	Hand S, Baker J, Smith AP, et al: Outpatient intensive chemotherapy for small cell lung cancer: five years experience of modified ‘ICE’ ifosfamide carboplatin and etoposide. Clin Oncol (R Coll Radiol). 14:367–371. 2002. View Article : Google Scholar : PubMed/NCBI
19	Zhou H, Wang A, Huang Z, et al: Randomized clinical trial of IEP and EP regimens in the treatment of patients with small cell lung cancer. Chin J Lung Cancer. 7:240–242. 2004.(In Chinese).
20	Wu C, Qi H, Dai Y, et al: Therapeutic efficacy of chemotherapy with VIP for small cell lung cancer. Chin J Lung Cancer. 7:151–153. 2004.(In Chinese).